A private company, advising the agency in charge of overseeing Medicare, has advised against reimbursing for biomarker tests. This recommendation has led to strong opposition from cancer specialists. These specialists argue that biomarker tests are crucial for developing effective treatment plans for cancer patients. Without reimbursement, access to these tests could be severely limited, impacting patient care and outcomes.
For patients like LeeAnne Loney, the decision against reimbursement has personal implications. In the summer of 2024, Loney faced a difficult choice regarding her treatment options. The availability and affordability of biomarker tests were critical elements of her decision-making process.